Literature DB >> 28131335

Posterior Reversible Encephalopathy Syndrome: A Review.

Jai Shankar1, Jillian Banfield2.   

Abstract

Radiologists may be the first to suggest the diagnosis of posterior reversible encephalopathy syndrome (PRES). PRES is associated with many diverse clinical entities, the most common of which are eclampsia, hypertension, and immunosuppressive treatment. Radiologists should be aware of the spectrum of imaging findings in PRES. When promptly recognized and treated, the symptoms and radiological abnormalities can be completely reversed. When unrecognized, patients can progress to ischemia, massive infarction, and death. In this review, we present an overview of the unique signs observed on computed tomography and magnetic resonance images in PRES that can help in the early diagnosis and treatment that is highly effective in this syndrome.
Copyright © 2016 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eclampsia; Hypertension; Immunosuppression; Posterior reversible encephalopathy syndrome

Mesh:

Year:  2017        PMID: 28131335     DOI: 10.1016/j.carj.2016.08.005

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  12 in total

1.  Posterior reversible encephalopathy syndrome, preeclampsia or stroke? A diagnostic dilemma.

Authors:  Vikesh Patel; Bhavna Ramachandran; Ifrah Omar
Journal:  BMJ Case Rep       Date:  2019-07-27

2.  A Case of Pediatric Posterior Reversible Encephalopathy Syndrome (PRES) Secondary to Post-streptococcal Glomerulonephritis: A Literature Review and Assessment of Treatment Modalities.

Authors:  Abdurrahman F Kharbat; Pedro Calles; Allison Ogle; Tetyana L Vasylyeva; Kerrie Pinkney
Journal:  Cureus       Date:  2022-05-18

Review 3.  Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists.

Authors:  C Dodson; T J Richards; D A Smith; N H Ramaiya
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-26       Impact factor: 3.825

4.  Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature.

Authors:  Yajuan Lv; Yan Zhang; Jiandong Zhang; Ning Liang; Fengjun Liu; Ruixue Liu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Posterior reversible encephalopathy syndrome, a clinically diverse and challenging disorder.

Authors:  Therese Chruickshank; Hanne Thoresen; Espen Benjaminsen; Francis Odeh
Journal:  Clin Case Rep       Date:  2020-04-14

6.  Obstructive ureteric calculus with superimposed infections causing reversible posterior leukoencephalopathy syndrome: A case report.

Authors:  Fei Xie; Yanli Cai; Lin Huang; Jianqiang Hao; Tianjin Ling; Seidu A Richard
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

7.  Posterior Reversible Encephalopathy Syndrome Is the Common Cause of New-Onset Seizures in the Peripartum Period: A Tertiary Hospital-Based Study in South India.

Authors:  Jagarlapudi Mk Murthy; Shyam K Jaiswal; Keshava Anand Gaade
Journal:  J Epilepsy Res       Date:  2021-06-30

8.  Posterior Reversible Encephalopathy Syndrome: A Rare Complication in COVID-19.

Authors:  Anwar J Alnass; Rahaf A Alamer; Hend H Alamri; Azzah A Alharthi; Majd A Assad; Mohammed K Al Sedran; Dunya A Bu-Izran; Bayan F Mirza; Amwaj A Almalki; Malak Alshammari
Journal:  Cureus       Date:  2021-10-01

9.  Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review.

Authors:  Xutong Li; Jie Chai; Zhi Wang; Lin Lu; Qingye Zhao; Jie Zhou; Fang Ju
Journal:  Onco Targets Ther       Date:  2018-07-30       Impact factor: 4.147

10.  Clinical and MRI Features of Posterior Reversible Encephalopathy Syndrome With Atypical Regions: A Descriptive Study With a Large Sample Size.

Authors:  Kunhua Li; Yang Yang; Dajing Guo; Dong Sun; Chuanming Li
Journal:  Front Neurol       Date:  2020-03-24       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.